Weekly Cosmetic Research Analysis

This mechanistic preclinical study demonstrates that intracellular lactate accumulation acidifies the cytoplasm, promoting mitochondrial dysfunction, PKR phosphorylation, ASC specking, NLRP3 assembly, caspase-1 activation, and IL‑1β release. Independently, lactic acid can directly cleave pro‑IL‑1β/IL‑18 at canonical caspase-1 sites (Asp116), and systemic lactate worsened inflammation and survival in a murine sepsis model, highlighting lactate as both an inflammasome activator and non-enzymatic cytokine processor.

Impact: Identifies lactate-driven intracellular acidification as a dual driver of inflammation—activating NLRP3 through mitochondrial/PKR pathways and directly processing cytokines—providing a mechanistic bridge between metabolic derangement and hyperinflammation with therapeutic implications.

Clinical Implications: Suggests interventions that modulate lactate production/clearance, intracellular pH, PKR signaling, or NLRP3 could attenuate IL‑1β/IL‑18–driven pathology in sepsis and inflammatory skin conditions; clinicians should be cautious using high‑concentration lactic acid procedures in inflamed tissue until safety is clarified.

This foundational mechanistic study identifies PACC1 as the principal proton-sensitive ion channel in keratinocytes that, when activated by acidification, drives chloride efflux, activates the JNK/AP‑1 pathway, upregulates KLK5/7, and promotes corneodesmosomal degradation and desquamation. Genetic knockout/knockdown, proton-sensing–deficient mutants, pharmacologic inhibition, and rescue experiments collectively establish causality and position PACC1 as a druggable node for barrier and exfoliation modulation.

Impact: Pinpoints a molecular proton sensor that mechanistically links epidermal acid microenvironment to protease-mediated desquamation, offering a novel target for therapies and cosmetic agents that aim to modulate exfoliation and barrier homeostasis.

Clinical Implications: Supports development of selective PACC1 modulators (inhibitors or agonists) for conditions requiring modulation of desquamation (e.g., ichthyosis, hyperkeratosis, controlled cosmetic peeling); highlights need for safety profiling in intact human skin.

In a randomized, double‑blind, placebo‑controlled trial (n=75), oral collagen tripeptide formulations improved dermal collagen density, hydration, elasticity, and optical skin metrics versus placebo. The liposomal formulation produced earlier onset and larger magnitude improvements, including a statistically significant reduction in wrinkle area at 8 weeks and superior elasticity gains versus the nonliposomal formulation, supporting the role of delivery technology in nutricosmetic efficacy.

Impact: Provides high-quality RCT evidence that formulation (liposomal delivery) significantly alters clinical outcomes for an oral cosmetic intervention, informing product development, labeling, and clinical counseling.

Clinical Implications: Clinicians and consumers should recognize that delivery format matters: liposomal collagen tripeptides may yield faster and greater improvements in elasticity and wrinkle reduction over ~8 weeks. Longer-term data are needed, but formulation choice can be part of shared decision-making for noninvasive anti-aging strategies.